CARM - Carisma Therapeutics Inc.
IEX Last Trade
0.4602
-0.001 -0.282%
Share volume: 5,669
Last Updated: Fri 27 Dec 2024 08:05:34 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.46
0.00
-0.28%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-08 | 2022-11-07 | 2023-02-28 | 2023-05-11 | 2023-08-10 | 2023-11-09 | 2024-04-01 | 2024-05-09 | |
Assets | |||||||||
Total Assets | 176.163 M | 199.724 M | 189.174 M | 156.132 M | 133.013 M | 106.784 M | 89.554 M | 73.795 M | |
Current Assets | 156.420 M | 192.358 M | 189.144 M | 144.502 M | 122.200 M | 97.565 M | 80.471 M | 60.953 M | |
Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Other Current Assets | 757.000 K | 527.000 K | 400.000 K | 5.535 M | 5.122 M | 3.428 M | 2.866 M | 4.438 M | |
Short Term Investments | 757.000 K | 527.000 K | 400.000 K | 5.535 M | 5.122 M | 3.428 M | 2.866 M | 4.438 M | |
Total Receivables | 14.119 M | 14.297 M | 825.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Current Cash | 141.544 M | 177.534 M | 166.919 M | 138.967 M | 117.078 M | 94.137 M | 77.605 M | 56.515 M | |
Total Non-current Assets | 19.743 M | 7.366 M | 30.000 K | 11.630 M | 10.813 M | 9.219 M | 9.083 M | 12.842 M | |
Property Plant Equipment | 30.000 K | 0.000 | 0.000 | 8.107 M | 7.590 M | 7.379 M | 6.764 M | 7.550 M | |
Other Assets | 42.000 K | 0.000 | 0.000 | 3.493 M | 3.193 M | 1.810 M | 2.319 M | 5.292 M | |
Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 176.163 M | 199.724 M | 189.174 M | 156.132 M | 133.013 M | 106.784 M | 89.554 M | 73.795 M | |
Total liabilities | 33.805 M | 34.695 M | 30.984 M | 70.062 M | 66.308 M | 60.486 M | 63.022 M | 62.900 M | |
Total current liabilities | 32.005 M | 34.695 M | 30.984 M | 21.477 M | 17.973 M | 12.951 M | 15.908 M | 13.141 M | |
Accounts Payable | 1.667 M | 514.000 K | 1.233 M | 4.614 M | 2.487 M | 2.409 M | 3.933 M | 2.166 M | |
Other liabilities | 1.800 M | 0.000 | 0.000 | 46.897 M | 46.809 M | 46.176 M | 46.786 M | 46.131 M | |
Current long term debt | 0.000 | 0.000 | 0.000 | 3.785 M | 3.701 M | 1.388 M | 544.000 K | 3.864 M | |
Long term debt | 0.000 | 0.000 | 0.000 | 1.688 M | 1.526 M | 1.359 M | 328.000 K | 3.628 M | |
Other liabilities | 1.800 M | 0.000 | 0.000 | 46.897 M | 46.809 M | 46.176 M | 46.786 M | 46.131 M | |
Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Total Shareholder equity | 142.358 M | 165.029 M | 158.190 M | 86.070 M | 66.705 M | 46.298 M | 26.532 M | 10.895 M | |
Common stock | 9.973 M | 10.023 M | 10.140 M | 12.784 M | 40.258 M | 40.286 M | 40.769 M | 40.938 M | |
Retained earnings | -349.024 M | -328.567 M | -336.141 M | -182.865 M | -202.741 M | -224.144 M | -245.102 M | -264.080 M |